Correction to: Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect (Journal of Pharmacology and Experimental Therapeutics (2002) 303 (1273-1282) DOI: 10.1124/jpet.102.042754;Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 1273-1282

  Kashfi, Khosrow ^a,b   Rayyan, Yaser ^c   Qiao, Leon L ^d   Williams, Jennie L ^a,c   Chen, Jie ^a   Del Soldato, Piero ^c   Traganos, Frank ^c   Rigas, Basil ^a,c  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; SULINDAC;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL CYCLE PHASE; CELL LINE; CELL PROLIFERATION; CELL RENEWAL; CELL STRUCTURE; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ELECTRON MICROSCOPY; ENZYME BLOOD LEVEL; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LUNG CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TISSUE TYPES; TONGUE CANCER;

EID: 0036894884     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.42754err     Document Type: Erratum

References (22)

1. Baek SJ, Kim KS, Nixon JB, Wilson LC, and Eling TE (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:901-908.
2. Baek SJ, Wilson LC, Lee CH, and Eling TE (2002) Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 301:1126-1131.
3. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, and Wallace JL (1998) Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 62:L367-L373.
4. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, and DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188.
5. Fiorrucci SS, Mencarelli L, Del Soldato A, and Morelli PA (2002) Gastrointestinal safety of a NO-releasing aspirin derivative (NCX 4016) in humans: A double blind placebo controlled endoscopic study. Gastroenterology 122:A-28.
6. Gansauge S, Gansauge F, Nussler AK, Rau B, Poch B, Schoenberg MH, and Beger HG (1997) Exogenous, but not endogenous, nitric oxide increases proliferation rates in senescent human fibroblasts. FEBS Lett 410:160-164.
7. 1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ 9:611-617.
8. Hanif R, Pittas A, Feng Y, Koutsos MI, Shiff SJ, Staiano-Coico L, and Rigas B (1995) NSAIDs inhibit the growth of colon cancer cell lines by a prostaglandin independent pathway. Gastroenterology 108:A478.
9. Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, and Lee JS (2002) Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 94:1023-1031.
10. Kaza CS, Kashfi K, and Rigas B (2002) Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat 67:107-120.
11. Melino G, Catani MV, Corazzari M, Guerrieri P, and Bernassola F (2000) Nitric oxide can inhibit apoptosis or switch it into necrosis. Cell Mol Life Sci 57:612-622.
12. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, and Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356-4362.
13. Park EA, Mynatt RL, Cook GA, and Kashfi K (1995) Insulin regulates enzyme activity, malonyl-CoA sensitivity and mRNA abundance of hepatic carnitine palmitoyltransferase-I. Biochem J 310:853-858.
14. Prescott SM and Fitzpatrick FA (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470:M69-M78.
15. Qiao L, Hanif R, Sphicas E, Shiff SJ, and Rigas B (1998a) Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol 55:53-64.
16. Qiao L, Shiff SJ, and Rigas B (1998b) Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells. Int J Cancer 76:99-104.
17. Rigas B and Shiff SJ (1999) Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenases and the cell cycle. Their interactions in colon cancer. Adv Exp Med Biol 470:119-126.
18. Rigas B and Shiff SJ (2000) Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 54:210-215.
19. Rigas B and Williams JL (2002) NO-releasing NSAIDs and colon cancer chemoprevention: A promising novel approach (Review). Int J Oncol 20:885-890.
20. Shiff SJ, Qiao L, Tsai LL, and Rigas B (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96:491-503.
21. Thun MJ, Henley SJ, and Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 94:252-266.
22. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, and Rigas B (2001) Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: Implications for colon cancer chemoprevention. Cancer Res 61:3285-3289.